RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

L. Paz-Ares, S. Senan, D. Planchard, L. Wang, A. Cheong, R. Slepetis, M. H. Nguyen, E. E. Vokes

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)67-67
JournalAnnals of Oncology
Publication statusPublished - Apr 2019

Cite this